Detection of structural damage key to glaucoma management
August 1st 2004New York-Structure does predict function, George A. (Jack) Cioffi, MD, told participants in the Glaucoma 2004 meeting here, and therefore measurement of the optic nerve head is important in assessing the presence and progression of the disease.
Research pointing to role of retinal iron overload in AMD
August 1st 2004Fort Lauderdale, FL-Accumulating evidence is providing support for the hypothesis that elevated iron levels in the retina may be a factor in the pathogenesis of age-related macular degeneration (AMD), said Joshua Dunaief, MD, PhD
Lutien/zeaxanthin associated with decreased risk of AMD
August 1st 2004Fort Lauderdale, FL-A new analysis of baseline data collected in participants of the Age-Related Eye Disease Study (AREDS) reveals a higher intake of lutein/zeaxanthin was associated with a decreased likelihood of having advanced age-related macular degen- eration (AMD). The results were reported by John Paul SanGiovanni, ScD, at the annual meeting of the Association for Re-search in Vision and Ophthalmology.
NSAID with BAK as comfortable as preservative-free formula
August 1st 2004Fort Lauderdale, FL-In a comparison of the comfort of two non-steroidal anti-inflammatory drug (NSAID) formulations, ketorolac tromethamine ophthalmic solution 0.4% with benzalkonium chloride (BAK) (Acular LS, Allergan) seemed to be as comfortable as preservative-free ketorolac tromethamine ophthalmic solution 0.5% (Acular PF, Allergan) based on ratings by 45 healthy volunteers who received two doses of the drops in a randomized, investigator-masked, single-center clinical trial
Corneal epithelial barrier function studied in eyes receiving fluoroquinolones
August 1st 2004Fort Lauderdale, FL- In a preliminary mouse model study of corneal epithelial permeability and barrier function, several differences were found be- tween gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) and moxifloxacin ophthalmic solu- tion 0.5% (Vigamox, Alcon) but the significance of these findings is unclear, ac- cording to Stephen C. Pflugfelder, MD, who presented a poster on this study at the annual meeting of the Association for Research in Vision and Ophthalmology
Diffusion through aging Bruch's membrane studied
August 1st 2004Fort Lauderdale, FL-Studies evaluating age-related changes in the diffusional status of macromolecular transport processes across Bruch's membrane may provide new insight into the pathophysiology of age-related macular degeneration (AMD) and suggest new targets for intervention, said Ali A. Hussain, PhD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Visual acuity benefit seen with SnET2 photodynamic therapy
August 1st 2004Fort Lauderdale, FL-The investigational drug tin ethyl etiopurpurin (SnET2) produced a visual acuity benefit and slowed the development of neovascular lesions in two phase III trials of SnET2 photodynamic therapy (PDT) (Miravant Medical Technologies) for the treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration, said Edgar L. Thomas, MD, Retina-Vitreous Associates, Los Angeles.
Pseudophakic uveitc eyes at risk for traeculectomy failure
August 1st 2004Fort Lauderdale, FL-Prior pseudophakia appears to be a risk factor for trabeculectomy failure in eyes with uveitic glaucoma, said K. Sheng Lim, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Scleral flap technique simplifies glaucoma device implantation
August 1st 2004Fort Lauderdale, FL-Experience with implantation of the Ex-PRESS miniature glaucoma device (Optonol Ltd.) under a scleral flap in high-risk eyes shows that it is a simple and effective technique for controlling IOP and reduces complications encountered with subconjunctival implantation, said Trevor R. Carmichael, MD, PhD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Survey study correlates glaucoma with cardiovascular risk
August 1st 2004Fort Lauderdale, FL-Results of the OPTIME Study show that cardiovascular risk factors are significantly more prevalent among patients with primary open-angle glaucoma (POAG) compared with unaffected controls, reported Nicola Orzalesi, MD, PhD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Combination regimen may offer best topical keratitis treatment
August 1st 2004New York-Results of an in vitro susceptibility study suggest a combination regimen consisting of clarithromycin and a fourth-generation fluoroquinolone may offer the best topical treatment for keratitis due to non-tuberculous Mycobacteria, said Mahendra K. Shah, MS.
New artificial cornea offers promise for transplant patients
August 1st 2004A new artificial cornea may offer hope to patients who have a history of multiple human donor cornea rejections. AlphaCor, manufactured by Australian-based Argus Biomedical Pty Ltd. and marketed by CooperVision Surgical Inc., is a biocompatible, flexible, one-piece artificial cornea that has been designed to replace a scarred or diseased native cornea in patients for whom corneal graft using human donor tissue is unsuitable.
Hypertonic saline is a promising alternative for LASEK flap creation
August 1st 2004Rishon Le-Zion, Israel-LASEK performed by using hypertonic saline (5% NaCl) to lift the flap may be a better alternative to alcohol-assisted LASEK, according to a recent randomized prospective study. Israeli researchers presented clinical trial results of the new method.
Relative toxicity of four ophthalmic antibiotics studied
August 1st 2004Fort Lauderdale, FL-In a comparison study that has implications for wound healing in surface ablation procedures, investigators found that four commonly used topical ophthalmic antibiotics-moxifloxacin (Vigamox, Alcon), levofloxacin (Quixin, Santen), gatifloxacin (Zymar, Allergan), and ofloxacin (Ocuflox, Allergan)-all showed evidence of toxicity on human corneal epithelial cells, with moxifloxacin causing the least amount of toxicity.
Alcon gets 2nd review of potential AMD treatment
August 1st 2004Fort Worth, TX-Alcon Inc. has filed the second of three parts of its "rolling" new drug application for anecortave acetate for depot suspension (Retaane) 15 mg, an investigational treatment for patients with wet age-related macular degeneration (AMD).
PRK recommended procedure for U.S. Naval aviators
August 1st 2004San Diego-U.S. Naval aviators can benefit from PRK in terms of restoration of visual acuity to 20/20 and enhanced flight performance, said David J. Tanzer, MD, surgical director, refractive surgery center, department of ophthalmology, Naval Medical Center, San Diego.
Glaucoma expert urges a new look at screening
August 1st 2004Fort Lauderdale, FL-More aggressive glaucoma screening methods and a better understanding of disease progression as well as its incidence and prevalence among various population groups are essential to lessening the devastating impact of this disease worldwide, said Harry A. Quigley, MD, during the 2004 Friedenwald Award lecture at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting.
Single-use microkeratome produces predictable flaps
July 15th 2004San Diego-The M2 single-use microkeratome with a 130-?m head (Moria, Antony, France) appears to produce predictable flap thickness without causing any significant complications during or after LASIK, according to Richard A. Norden, MD, FACS, who spoke during the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS).